Premium
Potentiation of Photodynamic Therapy with Hypericin by Mitomycin C in the Radiation‐induced Fibrosarcoma–1 Mouse Tumor Model ¶
Author(s) -
Chen Bin,
Ahmed Bissan,
Landuyt Willy,
Ni Yicheng,
Gaspar Robert,
Roskams Tania,
De Witte Peter A. M.
Publication year - 2003
Publication title -
photochemistry and photobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 131
eISSN - 1751-1097
pISSN - 0031-8655
DOI - 10.1562/0031-8655(2003)0780278poptwh2.0.co2
Subject(s) - hypericin , fibrosarcoma , long term potentiation , photodynamic therapy , mitomycin c , cancer research , radiation therapy , chemistry , medicine , pharmacology , pathology , surgery , receptor , organic chemistry
Hypericin, a polycyclic quinone obtained from plants of the genus Hypericum , has been shown to be a promising photosensitizer. We investigated the combination of hypericin–photodynamic therapy (PDT) and a bioreductive drug mitomycin C (MMC) in the present study. The radiation‐induced fibrosarcoma–1 tumors were exposed to laser light (120 J/cm 2 at 595 nm) 24 h after an intravenous injection of hypericin (1 mg/kg). Hypericin‐PDT alone significantly decreased tumor perfusion and oxygen tension as demonstrated by India ink staining technique and OxyLite pO 2 measurement, respectively. The in vivo–in vitro cell‐survival assay revealed about 60% direct tumor cell killing immediately after PDT. No significant delayed tumor cell death was observed after PDT, which suggests that vascular damage does not contribute significantly to the overall tumor cell death. Injection of a 2.5 mg/kg dose of MMC 20 min before light application significantly decreased tumor cell survival and delayed tumor growth compared with PDT or MMC alone. No greater skin reaction was observed after the combination of MMC and PDT than after PDT alone. Our study demonstrates that combining hypericin‐PDT with MMC can be effective in enhancing tumor response with little side effect.